Drug name - Piqray
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) | |
| CN102149711B | NOVARTIS | Organic Compounds |
Sep, 2029
(6 years from now) | |
| CN102149711A | NOVARTIS | Organic Compounds |
Sep, 2029
(6 years from now) | |
| IN307469B | NOVARTIS | The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide) |
Sep, 2029
(6 years from now) | |
| EP2331537A1 | NOVARTIS | 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases |
Sep, 2029
(6 years from now) | |
| EP2331537B1 | NOVARTIS | 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases |
Sep, 2029
(6 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
| 150MG | TABLET;ORAL | Prescription |
| 200MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.